Imunon (IMNN) 10-Q 10 Aug 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Aug. 07, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-15911
Entity Registrant Name	Imunon, Inc.
Entity Central Index Key	0000749647
Entity Tax Identification Number	52-1256615
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	997 Lenox Drive
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Lawrenceville
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08648
City Area Code	(609)
Local Phone Number	896-9100
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	IMNN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		9,367,855
Entity Information, Former Legal or Registered Name	NA

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,611,357	$ 11,492,841
Investment in debt securities - available for sale, at fair value	17,400,025	21,254,485
Accrued interest receivable on investment securities	80,489	128,932
Money market investments, restricted cash		1,500,000
Advances and deposits on clinical programs and other current assets	2,640,081	2,778,433
Total current assets	26,731,952	37,154,691
Property and equipment (at cost, less accumulated depreciation and amortization)	651,231	548,301
Other assets:
Money market investments, restricted cash		4,500,000
Deferred income tax asset		1,567,026
Operating lease right-of-use assets, net	1,288,511	155,876
Deposits and other assets	50,000	50,000
Total other assets	1,338,511	6,272,902
Total assets	28,721,694	43,975,894
Current liabilities:
Accounts payable – trade	2,612,440	3,586,623
Other accrued liabilities	3,233,193	4,794,936
Note payable – current portion, net of deferred financing costs		1,424,774
Operating lease liabilities - current portion	278,409	230,749
Total current liabilities	6,124,042	10,037,082
Notes payable – non-current portion, net of deferred financing costs		4,610,946
Operating lease liabilities - non-current portion	1,082,512
Total liabilities	7,206,554	14,648,028
Commitments and contingencies
Stockholders’ equity:
Preferred stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at June 30, 2023 and December 31, 2022)
Common stock - $0.01 par value (112,500,000 shares authorized; 9,252,003 and 7,436,219 shares issued at June 30, 2023 and December 31, 2022, respectively; 9,251,981 and 7,436,197 shares outstanding at June 30, 2023 and December 31, 2022, respectively)	92,520	74,362
Additional paid-in capital	401,163,818	397,980,023
Accumulated other comprehensive loss	162,045	26,494
Accumulated deficit	(379,818,055)	(368,667,825)
Total stockholders’ equity before treasury stock	21,600,328	29,413,054
Treasury stock, at cost (22 shares at June 30, 2023 and December 31, 2022)	(85,188)	(85,188)
Total stockholders’ equity	21,515,140	29,327,866
Total liabilities and stockholders’ equity	$ 28,721,694	$ 43,975,894

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	112,500,000	112,500,000
Common stock, shares issued	9,252,003	7,436,219
Common stock, shares outstanding	9,251,981	7,436,197
Treasury stock, shares	22	22

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Licensing revenue		$ 125,000		$ 250,000
Operating expenses:
Research and development	3,134,399	3,226,295	5,754,204	6,321,715
General and administrative	2,339,886	2,876,976	5,404,531	5,748,533
Total operating expenses	5,474,285	6,103,271	11,158,735	12,070,248
Loss from operations	(5,474,285)	(5,978,271)	(11,158,735)	(11,820,248)
Other (expense) income:
Investment income	281,673	40,355	534,743	52,459
Interest expense	(37,095)	(105,024)	(197,080)	(4,751,281)
Loss on extinguishment of debt	(329,158)		(329,158)
Other income		3		1,801
Total other (expense) income, net	(84,580)	(64,666)	8,505	(4,697,021)
Net loss	$ (5,558,865)	$ (6,042,937)	$ (11,150,230)	$ (16,517,269)
Net loss per common share, Basic	$ (0.61)	$ (0.87)	$ (1.28)	$ (2.59)
Net loss per common share, Diluted	$ (0.61)	$ (0.87)	$ (1.28)	$ (2.59)
Weighted average shares outstanding, Basic	9,136,573	6,981,970	8,711,389	6,372,908
Weighted average shares outstanding, Diluted	9,136,573	6,981,970	8,711,389	6,372,908

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Changes in:
Realized gains on debt securities recognized in investment income, net	$ 33,172	$ 21,596	$ 136,257	$ 23,934
Unrealized gains (losses) on debt securities, net	4,996	(32,652)	(705)	(85,994)
Change in realized and unrealized gains (losses) on available for sale securities, net	38,168	(11,056)	135,552	(62,060)
Net loss	(5,558,865)	(6,042,937)	(11,150,230)	(16,517,269)
Total comprehensive loss	$ (5,520,697)	$ (6,053,993)	$ (11,014,678)	$ (16,579,329)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (11,150,230)	$ (16,517,269)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	108,482	81,371
Amortization of right-of-use assets	272,675	260,583
Recognition of deferred revenue		(250,000)
Realized and unrealized gains (losses), net, on investment securities	135,551	(62,060)
Stock-based compensation	529,027	1,486,522
Realization of deferred income tax asset	1,567,026	1,383,446
Loss on extinguishment of debt	329,158
Amortization of deferred finance charges and debt discount associated with notes payable	55,122	90,630
Net changes in:
Accrued interest receivable on investment securities	48,443	79,116
Advances, deposits, and other current assets	138,352	(195,429)
Accounts payable and accrued liabilities	(2,811,064)	193,984
Net cash used in operating activities	(10,777,458)	(13,449,106)
Cash flows from investing activities:
Purchases of investment securities	(3,645,540)	(8,343,385)
Proceeds from sale and maturity of investment securities	7,500,000	22,775,000
Purchases of property and equipment	(211,412)	(166,022)
Net cash provided by investing activities	3,643,048	14,265,593
Cash flows from financing activities:
Proceeds from redeemable convertible preferred stock offering		28,500,000
Payment upon redemption of redeemable convertible preferred stock		(28,500,000)
Proceeds from sale of common stock equity, net of issuance costs	2,672,926	6,339,369
Payoff of the SVB loan and accrued end-of-term fees	(6,420,000)
Net cash (used in) provided by financing activities	(3,747,074)	6,339,369
Net change in cash, cash equivalents and restricted cash	(10,881,484)	7,155,856
Cash, cash equivalents and restricted cash at beginning of period	17,492,841	25,586,272
Cash, cash equivalents and restricted cash at end of period	6,611,357	32,742,128
Supplemental disclosures of cash flow information:
Interest paid	(179,542)	(4,267,107)
Recognition of right of use asset and liability	1,405,310
Cash paid for amounts included in measurement of lease liabilities:
Operating cash flows for lease payments	$ 340,457	$ 299,947

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member] Series A and B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2021		$ 57,705	$ 388,600,979	$ (85,188)	$ (7,974)	$ (332,769,591)	$ 55,795,931
Beginning Balance, shares at Dec. 31, 2021		5,770,516		22
Ending balance, value at Mar. 31, 2022		$ 57,705	389,595,593	$ (85,188)	(58,978)	(343,243,923)	46,265,209
Ending Balance, shares at Mar. 31, 2022		5,770,467
Beginning balance, value at Dec. 31, 2021		$ 57,705	388,600,979	$ (85,188)	(7,974)	(332,769,591)	55,795,931
Beginning Balance, shares at Dec. 31, 2021		5,770,516		22
Net loss						(16,517,269)	(16,517,269)
Sale of equity through equity financing facilities		$ 13,283	6,326,086				6,339,369
Sale of equity through equity financing facilities, net of costs, shares		1,328,274
Realized and unrealized gains and (losses), net, on investment securities					(62,060)		(62,060)
Stock-based compensation expense			1,486,522				1,486,522
Other
Other, shares		(49)
Issuance of preferred stock upon financing	$ 28,500,000
Issuance of preferred stock upon financing, shares	100,000
Redemption of preferred stock	$ (28,500,000)
Redemption of preferred stock, shares	(100,000)
Ending balance, value at Jun. 30, 2022		$ 70,988	396,413,587	$ (85,188)	(70,034)	(349,286,860)	47,042,493
Ending Balance, shares at Jun. 30, 2022		7,098,741		22
Beginning balance, value at Mar. 31, 2022		$ 57,705	389,595,593	$ (85,188)	(58,978)	(343,243,923)	46,265,209
Beginning Balance, shares at Mar. 31, 2022		5,770,467
Net loss						(6,042,937)	(6,042,937)
Sale of equity through equity financing facilities		$ 13,283	6,326,086				6,339,369
Sale of equity through equity financing facilities, net of costs, shares		1,328,274
Realized and unrealized gains and (losses), net, on investment securities					(11,056)		(11,056)
Stock-based compensation expense			491,908				491,908
Ending balance, value at Jun. 30, 2022		$ 70,988	396,413,587	$ (85,188)	(70,034)	(349,286,860)	47,042,493
Ending Balance, shares at Jun. 30, 2022		7,098,741		22
Beginning balance, value at Dec. 31, 2022		$ 74,362	397,980,023	$ (85,188)	26,494	(368,667,825)	29,327,866
Beginning Balance, shares at Dec. 31, 2022		7,436,219		22
Net loss						(11,150,230)	(11,150,230)
Sale of equity through equity financing facilities		$ 18,156	2,654,768				2,672,924
Sale of equity through equity financing facilities, net of costs, shares		1,815,584
Realized and unrealized gains and (losses), net, on investment securities					135,551		135,551
Stock-based compensation expense			529,027				529,027
Issuance of common stock upon exercise of options		$ 2					2
Issuance of common stock for restricted options, shares		200
Ending balance, value at Jun. 30, 2023		$ 92,520	401,163,818	$ (85,188)	162,045	(379,818,055)	21,515,140
Ending Balance, shares at Jun. 30, 2023		9,252,003		22
Beginning balance, value at Mar. 31, 2023		$ 90,970	400,776,487	$ (85,188)	123,877	(374,259,190)	26,646,956
Beginning Balance, shares at Mar. 31, 2023		9,097,027		22
Net loss						(5,558,865)	(5,558,865)
Sale of equity through equity financing facilities		$ 1,550	197,012				198,562
Sale of equity through equity financing facilities, net of costs, shares		154,976
Realized and unrealized gains and (losses), net, on investment securities					38,168		38,168
Stock-based compensation expense			190,319				190,319
Ending balance, value at Jun. 30, 2023		$ 92,520	$ 401,163,818	$ (85,188)	$ 162,045	$ (379,818,055)	$ 21,515,140
Ending Balance, shares at Jun. 30, 2023		9,252,003		22

Business Description

Business Description	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Business Description	Note 1. Business Description On September 19, 2022, Celsion Corporation announced a corporate name change to Imunon, Inc. (“Imunon” or the “Company”) reflecting the evolution of the Company’s business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Company’s common stock continues to trade on the Nasdaq Stock Market under the ticker symbol “IMNN.” Imunon is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon has two platform technologies: TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies, and PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is conducting preclinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate its PLACCINE platform. Imunon’s platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. The Company will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Note 2. Basis of Presentation The accompanying unaudited condensed consolidated financial statements, which include the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. All significant intercompany balances and transactions have been eliminated in consolidation. During the quarter ended June 30, 2023, there have been no changes to the Company’s accounting policies. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments, consisting only of normal recurring accruals considered necessary for a fair presentation, have been included in the accompanying unaudited condensed consolidated financial statements. Operating results for the six months ended June 30, 2023 and 2022, are not necessarily indicative of the results that may be expected for any other interim period(s) or for any full year. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2023. The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates, and assumptions that affect the amount reported in the Company’s financial statements and accompanying notes. Actual results could differ materially from those estimates. Events and conditions arising subsequent to the most recent balance sheet date have been evaluated for their possible impact on the unaudited condensed consolidated financial statements and accompanying notes. The Company has $ 24.1 1.8

New Accounting Pronouncements

New Accounting Pronouncements	6 Months Ended
	Jun. 30, 2023
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	Note 3. New Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued accounting pronouncements will not have a material impact on the Company’s condensed consolidated financial position, results of operations, and cash flows, or do not apply to its operations.

Restricted Cash

Restricted Cash	6 Months Ended
	Jun. 30, 2023
Receivables [Abstract]
Restricted Cash	Note 4. Restricted Cash As a condition of the SVB Loan Facility entered into on June 18, 2021, as further discussed in Note 10, the Company was required at all times to maintain on deposit with SVB as cash collateral in a segregated money market bank account in the name of the Company, unrestricted and unencumbered cash (other than a lien in favor of SVB) in an amount of at least 100% of the aggregate outstanding amount of the SVB loan facility. SVB may restrict withdrawals or transfers by or on behalf of the Company that would violate this requirement. The loan was repaid in full during the quarter ended June 30, 2023, thus removing this requirement. The required reserve totaled $ 6.0 The following table reconciles cash and cash equivalents and restricted cash per the condensed consolidated balance sheets to the condensed consolidated statements of cash flows: Schedule of Cash and Cash Equivalents and Restricted Cash June 30, 2023 December 31, 2022 Cash and cash equivalents $ 6,611,357 $ 11,492,841 Money market investments, restricted cash - 6,000,000 Total $ 6,611,357 $ 17,492,841

Net Loss per Common Share

Net Loss per Common Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Net Loss per Common Share	Note 5. Net Loss per Common Share Basic loss per share is calculated based upon the net loss available to common stockholders divided by the weighted average number of common shares outstanding during the period. Diluted loss per share is calculated after adjusting the denominator of the basic earnings per share computation for the effects of all dilutive potential common shares outstanding during the period. The dilutive effects of preferred stock, options and warrants and their equivalents are computed using the treasury stock method. The total number of shares of common stock issuable upon exercise of warrants, stock option grants and equity awards was 1,248,524 1,102,554

Investment in Debt Securities-A

Investment in Debt Securities-Available for Sale	6 Months Ended
	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Investment in Debt Securities-Available for Sale	Note 6. Investment in Debt Securities-Available for Sale Investments in debt securities available for sale with a fair value of $ 17,400,025 21,254,485 Investments in debt securities available for sale are evaluated periodically to determine whether a decline in their value is other than temporary. The term “other than temporary” is not intended to indicate a permanent decline in value. Rather, it means that the prospects for near term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. Management reviews criteria such as the magnitude and duration of the decline, as well as the reasons for the decline, to predict whether the loss in value is other than temporary. Once a decline in value is determined to be other than temporary, the value of the security is reduced and a corresponding charge to earnings is recognized. A summary of the cost, fair value and maturities of the Company’s short-term investments is as follows: Schedule of Cost, Fair Value and Maturities of Short Term Investments June 30, 2023 December 31, 2022 Cost Fair Value Cost Fair Value Short-term investments U.S. Treasury securities $ 5,960,208 $ 5,963,920 $ - $ - Corporate debt securities 11,277,772 11,436,105 21,227,991 21,254,485 Total $ 17,237,980 $ 17,400,025 $ 21,227,991 $ 21,254,485 June 30, 2023 December 31, 2022 Cost Fair Value Cost Fair Value Short-term investment maturities Within 3 months $ 10,765,740 $ 10,930,855 $ 4,005,559 $ 3,994,590 Between 3-12 months 6,472,240 6,469,170 17,222,432 17,259,895 Total $ 17,237,980 $ 17,400,025 $ 21,227,991 $ 21,254,485 The following table shows the Company’s investment in debt securities available for sale gross unrealized gains (losses) and fair value by investment category and length of time that individual securities have been in a continuous unrealized loss position at June 30, 2023 and December 31, 2022. The Company has reviewed individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary. Summary of Investment Securities Gross Unrealized Gains (Losses) June 30, 2023 December 31, 2022 Available for sale securities (all unrealized holding gains and losses are less than 12 months at date of measurement) Fair Value Unrealized Holding Gains (Losses) Fair Value Unrealized Holding Gains (Losses) Investments in debt securities with unrealized gains $ 13,412,665 $ 181,965 $ 13,278,505 $ 43,508 Investments in debt securities with unrealized losses 3,987,360 (19,920 ) 7,975,980 (17,014 ) Total $ 17,400,025 $ 162,045 $ 21,254,485 $ 26,494 Investment (loss) income, which includes net realized losses on sales of available for sale securities and investment income interest and dividends, is summarized as follows: Summary of Net Realized Losses On Sales of Available for Sale Securities and Investment Income Interest and Dividends 2023 2022 For the Three Months Ended June 30, 2023 2022 Interest and dividends accrued and paid $ 314,845 $ 61,951 Realized losses (33,172 ) (21,596 ) Investment income, net $ 281,673 $ 40,355 2023 2022 For the Six Months Ended June 30, 2023 2022 Interest and dividends accrued and paid $ 671,000 $ 76,393 Realized losses (136,257 ) (23,934 ) Investment income, net $ 534,743 $ 52,459

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Fair Value Measurements
Fair Value Measurements	Note 7. Fair Value Measurements FASB ASC Section 820, “Fair Value Measurements and Disclosures,” establishes a three-level hierarchy for fair value measurements which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: Level 1: Quoted prices (unadjusted) or identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date; Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and Level 3: Significant unobservable inputs that reflect a reporting entity’s own assumptions that market participants would use in pricing an asset or liability. Cash and cash equivalents, other current assets, accounts payable and other accrued liabilities are reflected in the condensed consolidated balance sheets at their approximate estimated fair values primarily due to their short-term nature. The fair values of securities available for sale is determined by relying on the securities’ relationship to other benchmark quoted securities and classified its investments as Level 2 items in both 2023 and 2022. There were no transfers of assets or liabilities between Level 1 and Level 2 and no transfers in or out of Level 3 during the six-month period ended June 30, 2023 or during the year ended December 31, 2022. The earnout milestone liability is valued using a risk-adjusted assessment of the probability of payment of each milestone, discounted to present value using an estimated time to achieve the milestone (see Note 13). Assets and liabilities measured at fair value are summarized below. Schedule of Fair Value, Assets and Liabilities Measured On Recurring Basis Total Fair Value Quoted Prices in Active Markets for Identical Assets/Liabilities Significant Other Observable Inputs (Level 2) Significant (Level 3) Assets: Recurring items as of June 30, 2023 Corporate debt securities and U.S. Treasury obligations, available for sale $ 17,400,025 $ – $ – $ 17,400,025 Recurring items as of December 31, 2022 Corporate debt securities, available for sale $ 21,254,485 $ – $ – $ 21,254,485

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 8. Intangible Assets In June 2014, the Company completed the acquisition of substantially all of the assets of EGEN, Inc., an Alabama corporation (“EGEN”), which changed its company name to EGWU, Inc. after the closing of the acquisition (the “EGEN Acquisition”). The Company acquired EGEN’s rights, title and interest in and to substantially all of the assets of EGEN, including cash and cash equivalents, patents, trademarks and other intellectual property rights, clinical data, certain contracts, licenses and permits, equipment, furniture, office equipment, furnishings, supplies and other tangible personal property. In addition, CLSN Laboratories assumed certain specified liabilities of EGEN, including the liabilities arising out of the acquired contracts and other assets relating to periods after the closing date. Acquired In-process Research and Development Acquired in-process research and development (“IPR&D”) consists of EGEN’s drug technology platforms: TheraPlas and TheraSilence. The fair value of the IPR&D drug technology platforms was estimated to be $ 24.2 As of December 31, 2022, the Company assessed whether there were indicators of impairment for the Company’s IPR&D and determined that the IPR&D asset was impaired during that period. Due to the continuing deterioration of public capital markets in the biotech industry in 2022 and its impact on market capitalization rates in this sector, IPR&D was reviewed for impairment. Having conducted a quantitative analysis of its IPR&D assets, the Company concluded the IPR&D asset was impaired during the fourth quarter of 2022. As of December 31, 2022, the Company wrote off the $ 13.4 13.4

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
Accrued Liabilities	Note 9. Accrued Liabilities Other accrued liabilities at June 30, 2023 and December 31, 2022 include the following: Schedule of Other Accrued Liabilities June 30, 2023 December 31, 2022 Amounts due to contract research organizations and other contractual agreements $ 1,698,511 $ 2,196,711 Accrued payroll and related benefits 1,458,082 2,139,927 Accrued interest - 37,583 Accrued professional fees 46,600 215,402 Other 30,000 205,313 Total $ 3,233,193 $ 4,794,936

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Notes Payable	Note 10. Notes Payable The SVB Loan Facility On June 18, 2021, the Company entered into a $ 10 6 6.0 The SVB Loan Facility is in the form of money market secured indebtedness bearing interest at a calculated WSJ Prime-based variable rate (currently 8.0 3 10 Payments under the loan agreement are interest only for the first 24 months after loan closing, followed by a 24-month amortization period of principal and interest through the scheduled maturity date. In connection with the SVB Loan Facility, the Company incurred financing fees and expenses totaling $ 243,370 3.0 300,000 26,667 59,709 10,429 45,315 141,958 109,084 55,122 90,630 On April 21, 2023, the Company repaid the outstanding principal balance, an early termination fee and the end-of-term charges in full satisfaction of the SVB Loan Facility. The following is a schedule of the amounts paid to SVB on April 21, 2023: SCHEDULE OF DEBT Principal balance at April 21, 2023 $ 6,000,000 Early termination fee 120,000 End-of-term charges 300,000 Total $ 6,420,000 During the three and six months ended June 30, 2023, the Company recorded a loss of $ 329,158 334,212

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Stockholders’ Equity	Note 11. Stockholders’ Equity On September 19, 2022, the Company announced a corporate name change to Imunon, Inc. The Company’s common stock will continue to trade on the Nasdaq Stock Market under the ticker symbol “IMNN” and its CUSIP number (15117N602) remained unchanged. Reverse Stock Split On February 28, 2022, the Company effected a 15-for-1 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on March 1, 2022. As of that date, each of the 15 shares of issued and outstanding common stock and equivalents was consolidated into one share of common stock. All shares have been restated to reflect the effects of the 15-for-1 reverse stock split. In addition, at the market open on March 1, 2022, the Company’s common stock started trading under a new CUSIP number 15117N602, although the Company’s ticker symbol, CLSN, remained unchanged. The reverse stock split was previously approved by the Company’s stockholders at the 2022 Special Meeting held on February 24, 2022, and the Company subsequently filed a Certificate of Amendment to its Certificate of Incorporation to effect the stock consolidation. Immediately prior to the reverse stock split, the Company had 86,557,736 5,770,467 6.6 0.4 2.5 0.2 At the Market Offering Agreement On May 25, 2022, the Company entered into an At the Market Offering Agreement (the “Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which the Company may offer and sell, from time to time, through Wainwright, shares of the Company’s common stock having an aggregate offering price of up to $ 7,500,000 336,075 503,798 1,815,584 2,672,924 Series A and Series B Convertible Redeemable Preferred Stock Offering On January 10, 2022, the Company entered into a Securities Purchase Agreement (the “Preferred Stock Purchase Agreement”) with several institutional investors, pursuant to which the Company agreed to issue and sell, in concurrent registered direct offerings (the “Preferred Offerings”), (i) 50,000 0.01 50,000 0.01 285 5 300 14.25 28.50 300 13.65 1,098,901 300 15.00 1,000,000 The Company held a special meeting of stockholders to consider an amendment (the “Amendment”) to the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of the outstanding shares of common stock (“Common Stock”) by a ratio to be determined by the Board of Directors of the Company (the “Reverse Stock Split”). The investors of the Preferred Stock Purchase Agreement had agreed to not transfer, offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of the shares of the Preferred Stock until the Reverse Stock Split, to vote the shares of the Series A Preferred Stock purchased in the Preferred Offerings in favor of such Amendment and to vote the shares of the Series B Preferred Stock purchased in the Preferred Offerings in a manner that “mirrors” the proportions on which the shares of Common Stock (excluding any shares of Common Stock that are not voted) and Series A Preferred Stock are voted on the Reverse Stock Split and the Amendment. Pursuant to the Preferred Stock Purchase Agreement, the Company filed two certificates of designation (the “Certificates of Designation”) with the Secretary of the State of Delaware designating the rights, preferences, and limitations of the shares of Preferred Stock. The Certificates of Designation provided, in particular, that the Preferred Stock had no voting rights, other than the right to vote as a class on certain specified matters, except that (i) each share of Series A Preferred Stock had the right to vote, on an as converted basis, on the Reverse Stock Split (together with the Company’s Common Stock and the Series B Preferred Stock as a single class), and (ii) each share of Series B Preferred Stock had the right to cast 3,000 votes per share of Series B Preferred Stock on the Reverse Stock Split. The holders of Preferred Stock were entitled to dividends, on an as-if converted basis, equal to dividends actually paid, if any, on shares of Common Stock. The Preferred Stock was convertible into shares of Common Stock at a rate of $ 13.65 15.00 Each holder of the Preferred Stock had the right to cause the Company to redeem all or part of their shares of the Preferred Stock from the earlier of receipt of stockholder approval of the Reverse Stock Split or of 90 days following the original issue date until 120 days following the original issue date, the “Redemption Date,” in cash at a redemption price equal to 105% of the stated value plus an amount equal to accumulated but unpaid dividends, if any, on such shares (whether or not earned or declared, but excluding interest on such dividends) up to, but excluding, the Redemption Date. 1,000,000 110,000 On March 3, 2022, the Company redeemed for cash at a price equal to 105% of the $ 300 50,000 50,000 The Series A Preferred Stock and Series B Preferred Stock were recorded as a liability on the condensed consolidated balance sheet during the first quarter of 2022 until the preferred shares were redeemed during the same quarter. The Company recognized $ 4,551,567 3,000,000 1,110,000 441,567 April 2022 Registered Direct Offering On April 6, 2022, the Company entered into a Securities Purchase Agreement (the “April 2022 Purchase Agreement”) with several institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “April 2022 Offering”), an aggregate of 1,328,274 5.27 7.0 In connection with the April 2022 Offering, the Company entered into a placement agent agreement with A.G.P./Alliance Global Partners (the “April 2022 Placement Agent”) pursuant to which the Company agreed to pay the April 2022 Placement Agent a cash fee equal to 6.5% of the aggregate gross proceeds raised from the sale of the securities sold in the April 2022 Offering and reimburse the April 2022 Placement Agent for certain of their expenses in an amount not to exceed $50,000.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 12. Stock-Based Compensation The Company has long-term compensation plans that permit the granting of equity-based awards in the form of stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, and performance awards. At the 2018 Annual Stockholders Meeting of the Company held on May 15, 2018, stockholders approved the 2018 Stock Incentive Plan (the “2018 Plan”). The 2018 Plan, as adopted, permits the granting of 180,000 80,000 260,000 166,667 426,667 513,333 940,000 1,030,000 1,970,000 The Company has issued stock awards to employees and directors in the form of stock options and restricted stock. Options are generally granted with strike prices equal to the fair market value of a share of common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning more than 10% of the outstanding stock of the Company must be at least 110% of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options. Option and restricted stock awards vest upon terms determined by the Compensation Committee of the Board of Directors and are subject to accelerated vesting in the event of a change of control or certain terminations of employment. The Company issues new shares to satisfy its obligations from the exercise of options or the grant of restricted stock awards. On July 19, 2022, September 27, 2022, December 13, 2022, March 17, 2023 and June 26, 2023, the Compensation Committee of the Board of Directors approved the grant of (i) inducement stock options (the “Inducement Option Grants”) to purchase a total of 177,000 8,501 19,000 5,230 5,000 63,000 2,250 4,000 1,100 1,000 1.95 1.65 1.40 1.32 1.28 214,751 As of June 30, 2023, there were a total of 1,975,073 802,363 1,172,710 A summary of stock option awards and restricted stock grants, inclusive of awards granted under the 2018 Stock Plan and Inducement Option Grants for the six-months ended June 30, 2023 is presented below. Summary of Stock Options Awards and Restricted Stock Grants Stock Options Restricted Stock Awards Weighted Average Options Outstanding Weighted Average Exercise Price Non-vested Restricted Stock Outstanding Weighted Average Grant Date Fair Value Contractual Terms of Equity Awards (in years) Equity awards outstanding at January 1, 2023 760,220 $ 4.55 69,650 $ 1.92 Equity awards granted 335,000 $ 1.32 2,100 $ 1.30 Equity Awards vested and issued - - (200 ) 4.60 Equity awards terminated (78,106 ) $ 7.30 (200 ) $ 4.60 Equity awards outstanding at June 30, 2023 1,017,114 $ 3.33 71,350 $ 1.89 9.1 Aggregate intrinsic value of outstanding equity awards at June 30, 2023 $ - $ - Equity awards exercisable at June 30, 2023 479,189 $ 4.70 8.9 Aggregate intrinsic value of equity awards exercisable at June 30, 2023 $ - Total compensation cost related to stock options and restricted stock awards amounted to approximately $ 0.5 1.5 0.1 0.5 0.4 1.0 As of June 30, 2023, there was $ 0.7 3 4 1.32 4.16 The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from the Company’s stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model: Schedule of Assumptions Used to Determine Fair Value of Options Granted For the Six Months Ended June 30, 2023 2022 Risk-free interest rate 3.72 % 1.74 % Expected volatility 107.03 113.64 % 108.5 % Expected life (in years) 9.0 10.0 8.5 9.0 Expected dividend yield 0.0 % 0.0 % Expected volatilities utilized in the model are based on historical volatility of the Company’s stock price. The risk-free interest rate is derived from values assigned to U.S. Treasury bonds with terms that approximate the expected option lives in effect at the time of grant.

Earn-Out Milestone Liability

Earn-Out Milestone Liability	6 Months Ended
	Jun. 30, 2023
Earn-out Milestone Liability
Earn-Out Milestone Liability	Note 13. Earn-Out Milestone Liability The total aggregate purchase price for the EGEN Acquisition included potential future earn-out payments contingent upon achievement of certain milestones. The difference between the aggregate $ 30.4 13.9 each milestone (10% to 67%) and utilizing a discount rate based on the estimated time to achieve the milestone (1.5 to 2.5 years). On March 28, 2019, the Company and EGWU, Inc. entered into an amendment to its purchase agreement (“Amended Asset Purchase Agreement”), whereby payment of the earnout milestone liability related to the Ovarian Cancer Indication of $ 12.4 a) $ 7.0 b) $ 12.4 At December 31, 2022, the Company wrote off the carrying value of the earn-out milestone liability as a result of the requirements not being achieved and recognized a non-cash gain of $ 5.4

Warrants

Warrants	6 Months Ended
	Jun. 30, 2023
Warrants
Warrants	Note 14. Warrants The following is a summary of all warrant activity for the three-month period ended June 30, 2023: Summary of Warrant Activity Warrants Number of Issued Weighted Average Exercise Price Warrants outstanding at December 31, 2022 168,519 $ 19.78 Warrants expired during the six months ended June 30, 2023 (8,459 ) $ 37.29 Warrants outstanding at June 30, 2023 160,060 $ 18.86 Aggregate intrinsic value of outstanding warrants at June 30, 2023 $ - Weighted average remaining contractual terms at June 30, 2023 2.7

Leases

Leases	6 Months Ended
	Jun. 30, 2023
Leases
Leases	Note 15. Leases In 2011, the Company executed a lease (the “Lease”) with Brandywine Operating Partnership, L.P. (“Brandywine”), a Delaware limited partnership, for a 10,870 66 st increase the size of the premises by 2,285 square feet to 9,850 square feet and also extended the lease term by one year to September 1, 2023. 25,035 27,088 nd 11,420 28,550 30,903 The following is a table of the lease payments and maturity of the Company’s operating lease liabilities as of June 30, 2023: Schedule of Lease Payments and Maturity of Operating Lease Liabilities 2023 $ 225,474 2024 348,881 2025 355,859 2026 362,976 Thereafter 401,139 Subtotal future lease payments 1,694,329 Less imputed interest (333,408 ) Total lease liabilities $ 1,360,921 Weighted average remaining life 4.44 Weighted average discount rate 9.98 % For the three-month and six-month periods ended June 30, 2023, operating lease expense was $ 165,446 324,722 173,753 340,457 For the three-month and six-month periods ended June 30, 2022, operating lease expense was $ 146,936 293,872 150,374 299,947

Technology Development and Lice

Technology Development and Licensing Agreements	6 Months Ended
	Jun. 30, 2023
Technology Development And Licensing Agreements
Technology Development and Licensing Agreements	Note 16. Technology Development and Licensing Agreements On May 7, 2012, the Company entered into a long-term commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. (“Hisun”) for the production of ThermoDox® in the China territory. In accordance with the terms of the agreement, Hisun will be responsible for providing all of the technical and regulatory support services, including the costs of all technical transfer, registration and bioequivalence studies, technical transfer costs, Imunon consultative support costs and the purchase of any necessary equipment and additional facility costs necessary to support capacity requirements for the manufacture of ThermoDox®. Imunon will repay Hisun for the aggregate amount of these development costs and fees commencing on the successful completion of three registration batches of ThermoDox®. Hisun is also obligated to meet certain performance requirements under the agreement. The agreement will initially be limited to a percentage of the production requirements of ThermoDox® in the China territory with Hisun retaining an option for additional global supply after local regulatory approval in the China territory. In addition, Hisun will collaborate with Imunon around the regulatory approval activities for ThermoDox® with the China State Food and Drug Administration. On January 18, 2013, the Company entered into a technology development contract with Hisun, pursuant to which Hisun paid it a non-refundable research and development fee of $ 5 5.0 10

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 17. Commitments and Contingencies On October 29, 2020, a putative securities class action was filed against the Company and certain of its officers and directors (the “Spar Individual Defendants”) in the U.S. District Court for the District of New Jersey, captioned Spar v. Celsion Corporation, et al., Case No. 1:20-cv-15228. The plaintiff alleged that the Company and Individual Defendants made false and misleading statements regarding one of the Company’s drug candidates, ThermoDox®, and brings claims for damages under Section 10(b) of the Exchange Act and Rule 10b-5 promulgated thereunder against all Defendants, and under Section 20(a) of the Exchange Act of 1934 against the Individual Defendants. At this stage of the case neither the likelihood that a loss, if any, will be realized, nor an estimate of possible loss or range of loss, if any, can be determined. On February 6, 2023, the U.S. District Court granted a Motion to Dismiss filed by the Company and Spar Individual Defendants and granted Plaintiff leave to file an amended complaint within 30 days. Plaintiff did not file an amended complaint within the 30-day deadline. In February 2021, a derivative shareholder lawsuit was filed against the Company, as the nominal defendant, and certain of its directors and officers as defendants in the U.S. District Court for the District of New Jersey, captioned Fidler v. Michael H. Tardugno, et al., Case No. 3:21-cv-02662. The plaintiff alleges breach of fiduciary duty and other claims arising out of alleged statements made by certain of the Company’s directors and/or officers regarding ThermoDox®. The Company believes it has meritorious defenses to these claims and intends to vigorously contest this suit. At this stage of the case neither the likelihood that a loss, if any, will be realized, nor an estimate of possible loss or range of loss, if any, can be determined. In August 2021, a complaint regarding a corporate books and records demand was filed against the Company in the Court of Chancery of the State of Delaware, captioned Pacheco v. Celsion Corporation, Case No. 2021-0705. The plaintiff alleged he was entitled to inspect the Company’s books and records concerning the OPTIMA Study and other materials. On May 31, 2023, the Court of Chancery entered the parties’ stipulation dismissing the case without prejudice. In October 2021, an arbitration was commenced against the Company before the CPR Institute for Conflict Prevention & Resolution, captioned Curia New Mexico, LLC v. Celsion Corp., Case No. G-22-85-S. The claimant alleged that the Company failed to pay invoices for the manufacture of two batches of ThermoDox®. On April 19, 2023, the arbitral tribunal issued an interim award, upholding claimant’s claim with respect to one of the two batches of ThermoDox® for an aggregate amount of approximately $ 583,500

Related Party Transaction

Related Party Transaction	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Related Party Transaction	Note 18. Related Party Transaction On November 16, 2022, the Company entered into a Convertible Note Purchase Agreement with Transomic Technologies, Inc. (“Transomic”) whereby the Company purchased $ 375,000 5

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 19. Subsequent Events The Company has evaluated its subsequent events from June 30, 2023, through the date these condensed consolidated financial statements were issued.

Restricted Cash (Tables)

Restricted Cash (Tables)	6 Months Ended
	Jun. 30, 2023
Receivables [Abstract]
Schedule of Cash and Cash Equivalents and Restricted Cash	The following table reconciles cash and cash equivalents and restricted cash per the condensed consolidated balance sheets to the condensed consolidated statements of cash flows: Schedule of Cash and Cash Equivalents and Restricted Cash June 30, 2023 December 31, 2022 Cash and cash equivalents $ 6,611,357 $ 11,492,841 Money market investments, restricted cash - 6,000,000 Total $ 6,611,357 $ 17,492,841

Investment in Debt Securities_2

Investment in Debt Securities-Available for Sale (Tables)	6 Months Ended
	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Schedule of Cost, Fair Value and Maturities of Short Term Investments	Schedule of Cost, Fair Value and Maturities of Short Term Investments June 30, 2023 December 31, 2022 Cost Fair Value Cost Fair Value Short-term investments U.S. Treasury securities $ 5,960,208 $ 5,963,920 $ - $ - Corporate debt securities 11,277,772 11,436,105 21,227,991 21,254,485 Total $ 17,237,980 $ 17,400,025 $ 21,227,991 $ 21,254,485 June 30, 2023 December 31, 2022 Cost Fair Value Cost Fair Value Short-term investment maturities Within 3 months $ 10,765,740 $ 10,930,855 $ 4,005,559 $ 3,994,590 Between 3-12 months 6,472,240 6,469,170 17,222,432 17,259,895 Total $ 17,237,980 $ 17,400,025 $ 21,227,991 $ 21,254,485
Summary of Investment Securities Gross Unrealized Gains (Losses)	The following table shows the Company’s investment in debt securities available for sale gross unrealized gains (losses) and fair value by investment category and length of time that individual securities have been in a continuous unrealized loss position at June 30, 2023 and December 31, 2022. The Company has reviewed individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary. Summary of Investment Securities Gross Unrealized Gains (Losses) June 30, 2023 December 31, 2022 Available for sale securities (all unrealized holding gains and losses are less than 12 months at date of measurement) Fair Value Unrealized Holding Gains (Losses) Fair Value Unrealized Holding Gains (Losses) Investments in debt securities with unrealized gains $ 13,412,665 $ 181,965 $ 13,278,505 $ 43,508 Investments in debt securities with unrealized losses 3,987,360 (19,920 ) 7,975,980 (17,014 ) Total $ 17,400,025 $ 162,045 $ 21,254,485 $ 26,494
Summary of Net Realized Losses On Sales of Available for Sale Securities and Investment Income Interest and Dividends	Investment (loss) income, which includes net realized losses on sales of available for sale securities and investment income interest and dividends, is summarized as follows: Summary of Net Realized Losses On Sales of Available for Sale Securities and Investment Income Interest and Dividends 2023 2022 For the Three Months Ended June 30, 2023 2022 Interest and dividends accrued and paid $ 314,845 $ 61,951 Realized losses (33,172 ) (21,596 ) Investment income, net $ 281,673 $ 40,355 2023 2022 For the Six Months Ended June 30, 2023 2022 Interest and dividends accrued and paid $ 671,000 $ 76,393 Realized losses (136,257 ) (23,934 ) Investment income, net $ 534,743 $ 52,459

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Measurements
Schedule of Fair Value, Assets and Liabilities Measured On Recurring Basis	Assets and liabilities measured at fair value are summarized below. Schedule of Fair Value, Assets and Liabilities Measured On Recurring Basis Total Fair Value Quoted Prices in Active Markets for Identical Assets/Liabilities Significant Other Observable Inputs (Level 2) Significant (Level 3) Assets: Recurring items as of June 30, 2023 Corporate debt securities and U.S. Treasury obligations, available for sale $ 17,400,025 $ – $ – $ 17,400,025 Recurring items as of December 31, 2022 Corporate debt securities, available for sale $ 21,254,485 $ – $ – $ 21,254,485

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
Schedule of Other Accrued Liabilities	Other accrued liabilities at June 30, 2023 and December 31, 2022 include the following: Schedule of Other Accrued Liabilities June 30, 2023 December 31, 2022 Amounts due to contract research organizations and other contractual agreements $ 1,698,511 $ 2,196,711 Accrued payroll and related benefits 1,458,082 2,139,927 Accrued interest - 37,583 Accrued professional fees 46,600 215,402 Other 30,000 205,313 Total $ 3,233,193 $ 4,794,936

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
SCHEDULE OF DEBT	On April 21, 2023, the Company repaid the outstanding principal balance, an early termination fee and the end-of-term charges in full satisfaction of the SVB Loan Facility. The following is a schedule of the amounts paid to SVB on April 21, 2023: SCHEDULE OF DEBT Principal balance at April 21, 2023 $ 6,000,000 Early termination fee 120,000 End-of-term charges 300,000 Total $ 6,420,000

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Stock Options Awards and Restricted Stock Grants	A summary of stock option awards and restricted stock grants, inclusive of awards granted under the 2018 Stock Plan and Inducement Option Grants for the six-months ended June 30, 2023 is presented below. Summary of Stock Options Awards and Restricted Stock Grants Stock Options Restricted Stock Awards Weighted Average Options Outstanding Weighted Average Exercise Price Non-vested Restricted Stock Outstanding Weighted Average Grant Date Fair Value Contractual Terms of Equity Awards (in years) Equity awards outstanding at January 1, 2023 760,220 $ 4.55 69,650 $ 1.92 Equity awards granted 335,000 $ 1.32 2,100 $ 1.30 Equity Awards vested and issued - - (200 ) 4.60 Equity awards terminated (78,106 ) $ 7.30 (200 ) $ 4.60 Equity awards outstanding at June 30, 2023 1,017,114 $ 3.33 71,350 $ 1.89 9.1 Aggregate intrinsic value of outstanding equity awards at June 30, 2023 $ - $ - Equity awards exercisable at June 30, 2023 479,189 $ 4.70 8.9 Aggregate intrinsic value of equity awards exercisable at June 30, 2023 $ -
Schedule of Assumptions Used to Determine Fair Value of Options Granted	The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from the Company’s stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model: Schedule of Assumptions Used to Determine Fair Value of Options Granted For the Six Months Ended June 30, 2023 2022 Risk-free interest rate 3.72 % 1.74 % Expected volatility 107.03 113.64 % 108.5 % Expected life (in years) 9.0 10.0 8.5 9.0 Expected dividend yield 0.0 % 0.0 %

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2023
Warrants
Summary of Warrant Activity	The following is a summary of all warrant activity for the three-month period ended June 30, 2023: Summary of Warrant Activity Warrants Number of Issued Weighted Average Exercise Price Warrants outstanding at December 31, 2022 168,519 $ 19.78 Warrants expired during the six months ended June 30, 2023 (8,459 ) $ 37.29 Warrants outstanding at June 30, 2023 160,060 $ 18.86 Aggregate intrinsic value of outstanding warrants at June 30, 2023 $ - Weighted average remaining contractual terms at June 30, 2023 2.7

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2023
Leases
Schedule of Lease Payments and Maturity of Operating Lease Liabilities	The following is a table of the lease payments and maturity of the Company’s operating lease liabilities as of June 30, 2023: Schedule of Lease Payments and Maturity of Operating Lease Liabilities 2023 $ 225,474 2024 348,881 2025 355,859 2026 362,976 Thereafter 401,139 Subtotal future lease payments 1,694,329 Less imputed interest (333,408 ) Total lease liabilities $ 1,360,921 Weighted average remaining life 4.44 Weighted average discount rate 9.98 %

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Cash and cash equivalents, short-term investments	$ 24,100,000		$ 24,100,000
Operating losses	$ (5,558,865)	$ (6,042,937)	(11,150,230)	$ (16,517,269)
NEW JERSEY
Operating losses			$ 1,800,000

Schedule of Cash and Cash Equiv

Schedule of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Receivables [Abstract]
Cash and cash equivalents	$ 6,611,357	$ 11,492,841
Money market investments, restricted cash		6,000,000
Total	$ 6,611,357	$ 17,492,841

Restricted Cash (Details Narrat

Restricted Cash (Details Narrative) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Line of Credit Facility [Line Items]
Restricted investments		$ 6,000,000
Silicon Valley Bank [Member]
Line of Credit Facility [Line Items]
Restricted investments		$ 6,000,000

Net Loss per Common Share (Deta

Net Loss per Common Share (Details Narrative) - shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Anti-dilutive securities	1,248,524	1,102,554

Schedule of Cost, Fair Value an

Schedule of Cost, Fair Value and Maturities of Short Term Investments (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Marketable Securities [Line Items]
Short-term investments - Cost	$ 17,237,980	$ 21,227,991
Short-term investments - Fair Value	17,400,025	21,254,485
Short-term investment maturities - Within 3 months, cost	10,765,740	4,005,559
Short-term investment maturities - Within 3 months, fair value	10,930,855	3,994,590
Short-term investment maturities - Between 3-12 months, cost	6,472,240	17,222,432
Short-term investment maturities - Between 3-12 months, fair value	6,469,170	17,259,895
Total, cost	17,237,980	21,227,991
Total, fair value	17,400,025	21,254,485
US Treasury Securities [Member]
Marketable Securities [Line Items]
Short-term investments - Cost	5,960,208
Short-term investments - Fair Value	5,963,920
Corporate Debt Securities [Member]
Marketable Securities [Line Items]
Short-term investments - Cost	11,277,772	21,227,991
Short-term investments - Fair Value	$ 11,436,105	$ 21,254,485

Summary of Investment Securitie

Summary of Investment Securities Gross Unrealized Gains (Losses) (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Investments with unrealized gains, Fair Value	$ 13,412,665	$ 13,278,505
Investments with unrealized gains, Unrealized Holding Gains (Losses)	181,965	43,508
Investments with unrealized losses, Fair Value	3,987,360	7,975,980
Investments with unrealized Losses, Unrealized Holding Gains (Losses)	(19,920)	(17,014)
Total, Fair Value	17,400,025	21,254,485
Total, Unrealized Holding Gains (Losses)	$ 162,045	$ 26,494

Summary of Net Realized Losses

Summary of Net Realized Losses On Sales of Available for Sale Securities and Investment Income Interest and Dividends (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Interest and dividends accrued and paid	$ 314,845	$ 61,951	$ 671,000	$ 76,393
Realized losses	(33,172)	(21,596)	(136,257)	(23,934)
Investment income, net	$ 281,673	$ 40,355	$ 534,743	$ 52,459

Investment in Debt Securities_3

Investment in Debt Securities-Available for Sale (Details Narrative) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Investment in debt securities - available for sale, at fair value	$ 17,400,025	$ 21,254,485

Schedule of Fair Value, Assets

Schedule of Fair Value, Assets and Liabilities Measured On Recurring Basis (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value	$ 17,400,025	$ 21,254,485
Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value	11,436,105	21,254,485
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value	17,400,025	21,254,485
Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value
Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value
Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value	$ 17,400,025	$ 21,254,485

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - In Process Research and Development [Member] - USD ($) $ in Millions	3 Months Ended	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2023	Dec. 31, 2022
EGEN Inc [Member] | IPR and D Drug Technology Platforms [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated acquisition price		$ 24.2
IPR and D Drug Technology Platforms [Member]
Finite-Lived Intangible Assets [Line Items]
Asset impairment charges			$ 13.4
Non-cash charge	$ 13.4

Schedule of Other Accrued Liabi

Schedule of Other Accrued Liabilities (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Amounts due to contract research organizations and other contractual agreements	$ 1,698,511	$ 2,196,711
Accrued payroll and related benefits	1,458,082	2,139,927
Accrued interest		37,583
Accrued professional fees	46,600	215,402
Other	30,000	205,313
Total	$ 3,233,193	$ 4,794,936

SCHEDULE OF DEBT (Details)

SCHEDULE OF DEBT (Details) - Horizon Technology Finance Corporation [Member]	Apr. 21, 2023 USD ($)
Principal balance at April 21, 2023	$ 6,000,000
Early termination fee	120,000
End-of-term charges	300,000
Total	$ 6,420,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
	Jun. 18, 2021	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Line of Credit Facility [Line Items]
Interest expense debt		$ 37,095	$ 105,024	$ 197,080	$ 4,751,281
Horizon Credit Agreement [Member]
Line of Credit Facility [Line Items]
Gain (loss) on contract termination				329,158
Silicon Valley Bank [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 10,000,000
Proceeds from lines of credit	6,000,000
Restricted cash	$ 6,000,000
Debt instrument, interest rate	8%
Final payment percentage	3%
Long term line of credit	$ 10,000,000
Debt instrument, description	Payments under the loan agreement are interest only for the first 24 months after loan closing, followed by a 24-month amortization period of principal and interest through the scheduled maturity date.
Financing fees and expenses	$ 243,370
End of term charge percentage	3%
Interest expense debt	$ 300,000			334,212
Interest expense, debt		26,667	59,709	141,958	109,084
Amortization of debt issuance costs		10,429	$ 45,315	$ 55,122	$ 90,630
Gain (loss) on contract termination		$ 329,158

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)					3 Months Ended			6 Months Ended		12 Months Ended
	Apr. 19, 2023	May 25, 2022	Apr. 06, 2022	Jan. 10, 2022	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Mar. 03, 2022	Jan. 13, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock split, description								On February 28, 2022, the Company effected a 15-for-1 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on March 1, 2022. As of that date, each of the 15 shares of issued and outstanding common stock and equivalents was consolidated into one share of common stock. All shares have been restated to reflect the effects of the 15-for-1 reverse stock split. In addition, at the market open on March 1, 2022, the Company’s common stock started trading under a new CUSIP number 15117N602, although the Company’s ticker symbol, CLSN, remained unchanged.
Reverse stock split common stock outstanding								5,770,467
Common stock, shares outstanding					9,251,981			9,251,981		7,436,197
Stock issued during period, value, new issues					$ 198,562	$ 6,339,369		$ 2,672,924	$ 6,339,369
Preferred stock, shares issued					0			0		0
Preferred stock, stated value				$ 300	$ 0.01			$ 0.01		$ 0.01	$ 300
Proceeds from issuance of preferred stock				$ 28,500,000
Common stock, par value					$ 0.01			$ 0.01		$ 0.01
Redemption term description								Each holder of the Preferred Stock had the right to cause the Company to redeem all or part of their shares of the Preferred Stock from the earlier of receipt of stockholder approval of the Reverse Stock Split or of 90 days following the original issue date until 120 days following the original issue date, the “Redemption Date,” in cash at a redemption price equal to 105% of the stated value plus an amount equal to accumulated but unpaid dividends, if any, on such shares (whether or not earned or declared, but excluding interest on such dividends) up to, but excluding, the Redemption Date.
Placement agent fees								$ 1,000,000
Preferred stock, shares outstanding					0			0		0
Shares issued, redemption value
Legal fees	$ 583,500
Proceeds from issuance of common stock								$ 2,672,926	6,339,369
Series A Convertible Redeemable Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares issued				50,000
Preferred stock, stated value				$ 0.01
Share price				$ 300
OriginalIssueDiscountRate				5%
Preferred stock, conversion price				$ 13.65
Conversion of stock, shares issued				1,098,901
Common stock, par value				$ 13.65
Preferred stock, shares outstanding											50,000
Series B Convertible Redeemable Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares issued				50,000
Preferred stock, stated value				$ 0.01
Share price				$ 285								$ 300
Proceeds from issuance of preferred stock				$ 14,250,000
Preferred stock, conversion price												$ 15
Conversion of stock, shares issued												1,000,000
Common stock, par value				$ 15
Preferred stock, shares outstanding											50,000
Series A & B Preferred [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense on preferred stock							$ 4,551,567
Shares issued, redemption value							3,000,000
Proceeds from issuance under placement							1,110,000
Legal fees							$ 441,567
Market Offering Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, value, new issues		$ 7,500,000
Number of shares sold								1,815,584		336,075
Proceeds from sale of stock								$ 2,672,924		$ 503,798
Preferred Stock Purchase Agreement [Member] | Series B Convertible Redeemable Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, voting rights				right to cast 3,000 votes per share of Series B Preferred Stock on the Reverse Stock Split.
Securities Purchase Agreement [Member] | April 2022 Registered Direct Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share price			$ 5.27
Stock issued, shares			1,328,274
Proceeds from issuance of common stock			$ 7,000,000
Placement agent fee description			In connection with the April 2022 Offering, the Company entered into a placement agent agreement with A.G.P./Alliance Global Partners (the “April 2022 Placement Agent”) pursuant to which the Company agreed to pay the April 2022 Placement Agent a cash fee equal to 6.5% of the aggregate gross proceeds raised from the sale of the securities sold in the April 2022 Offering and reimburse the April 2022 Placement Agent for certain of their expenses in an amount not to exceed $50,000.
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares outstanding					6,600,000			6,600,000
Warrants issued					2,500,000			2,500,000
Payments of stock issuance costs								$ 110,000
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares outstanding					400,000			400,000
Warrants issued					200,000			200,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock split common stock outstanding								86,557,736
Stock issued during period, value, new issues					$ 1,550	$ 13,283		$ 18,156	13,283
Shares issued, redemption value
Stock issued, shares					154,976	1,328,274		1,815,584	1,328,274

Summary of Stock Options Awards

Summary of Stock Options Awards and Restricted Stock Grants (Details) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average exercise price, granted	$ 1.32	$ 4.16
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding, beginning balance	760,220
Weighted average exercise price, beginning balance	$ 4.55
Options outstanding, granted	335,000
Weighted average exercise price, granted	$ 1.32
Options outstanding, vested and issued
Weighted average exercise price, vested and issued
Options outstanding, Terminated	(78,106)
Weighted average exercise price, Terminated	$ 7.30
Options outstanding, ending balance	1,017,114
Weighted average exercise price, ending balance	$ 3.33
Weighted average contractual terms	9 years 1 month 6 days
Options outstanding, aggregate intrinsic value
Options outstanding, exercisable	479,189
Weighted average exercise price, exercisable	$ 4.70
Weighted average contractual terms, exercisable	8 years 10 months 24 days
Options outstanding, aggregate intrinsic value, exercisable
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Non-vested stock awards, beginning balance	69,650
Weighted average grant date fair value, beginning balance	$ 1.92
Non-vested stock awards, granted	2,100
Weighted average grant date fair value, granted	$ 1.30
Non-vested stock awards, vested and issued	(200)
Weighted average grant date fair value, vested and issued	$ 4.60
Non-vested stock awards, Terminated	(200)
Weighted average grant date fair value, Terminated	$ 4.60
Non-vested stock awards, ending balance	71,350
Weighted average grant date fair value, ending balance	$ 1.89
Non-vested stock awards, aggregate intrinsic value

Schedule of Assumptions Used to

Schedule of Assumptions Used to Determine Fair Value of Options Granted (Details)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	3.72%	1.74%
Expected volatility, minimum	107.03%
Expected volatility, maximum	113.64%
Expected volatility		108.50%
Expected dividend yield	0%	0%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected life (in years)	9 years	8 years 6 months
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected life (in years)	10 years	9 years

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Millions						3 Months Ended		6 Months Ended
	Jun. 26, 2023	Mar. 17, 2023	Dec. 13, 2022	Sep. 27, 2022	Jul. 19, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 14, 2023	Dec. 31, 2022	Jun. 10, 2021	Jun. 15, 2020	May 14, 2019	May 15, 2018
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted, weighted average exercise price								$ 1.32	$ 4.16
Common stock, outstanding						9,251,981		9,251,981			7,436,197
Unrecognized share based compensation						$ 0.7		$ 0.7
Inducement Awards [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, outstanding						214,751		214,751
Equity Stock Awards [Member] | Granted Under 2018 Plan and 2007 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, reserved for future issuance						802,363		802,363
Stock Options and Restricted Stock Awards [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation								$ 0.5	$ 1.5
Stock Options and Restricted Stock Awards [Member] | Research and Development Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation								0.1	0.5
Stock Options and Restricted Stock Awards [Member] | General and Administrative Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation								$ 0.4	$ 1
Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares issued, shares						154,976	1,328,274	1,815,584	1,328,274
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, outstanding						400,000		400,000
Unrecognized share based compensation, period								3 years
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, outstanding						6,600,000		6,600,000
Unrecognized share based compensation, period								4 years
2018 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based payment award, shares authorized															180,000
Shares available for issuance						1,172,710		1,172,710
Common stock, reserved for future issuance						1,975,073		1,975,073
2018 Stock Incentive Plan [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares available for issuance										1,030,000		513,333	166,667	80,000
2018 Stock Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares available for issuance										1,970,000		940,000	426,667	260,000
2007 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options, strike price description								Options are generally granted with strike prices equal to the fair market value of a share of common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning more than 10% of the outstanding stock of the Company must be at least 110% of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options.
Inducement Option Grants [Member] | Ten New Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted, weighted average exercise price	$ 1.28	$ 1.32	$ 1.40	$ 1.65	$ 1.95
Inducement Option Grants [Member] | Ten New Employees [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares issued, shares	1,000	1,100	4,000	2,250	63,000
Inducement Option Grants [Member] | Ten New Employees [Member] | Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares issued, shares	5,000	5,230	19,000	8,501	177,000

Earn-Out Milestone Liability (D

Earn-Out Milestone Liability (Details Narrative) - USD ($) $ in Millions		12 Months Ended
	Jun. 20, 2014	Dec. 31, 2022	Mar. 28, 2019
EGWC, Inc [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Earnout payment options description	each milestone (10% to 67%) and utilizing a discount rate based on the estimated time to achieve the milestone (1.5 to 2.5 years).
Non-cash charge on earnout milestone liability		$ 5.4
Amended Asset Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Earnout milestone liability	$ 13.9		$ 12.4
Amended Asset Purchase Agreement [Member] | Within One Year of Achieving Milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Earnout milestone liability	$ 30.4
Amended Asset Purchase Agreement [Member] | 10 Business Days of Achieving Milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Earnout milestone liability			$ 7

Summary of Warrant Activity (De

Summary of Warrant Activity (Details)	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Warrants
Number of Warrants Issued, Warrants outstanding, Beginning balance | shares	168,519
Weighted Average Exercise Price, Warrants outstanding, Beginning balance | $ / shares	$ 19.78
Number of Warrants Issued, warrants expired | shares	(8,459)
Weighted Average Exercise Price, Warrants expired | $ / shares	$ 37.29
Number of Warrants Issued, Warrants outstanding, Ending balance | shares	160,060
Weighted Average Exercise Price, Warrants outstanding, Ending balance | $ / shares	$ 18.86
Aggregate intrinsic value of outstanding warrants | $
Weighted average remaining contractual terms (years)	2 years 8 months 12 days

Schedule of Lease Payments and

Schedule of Lease Payments and Maturity of Operating Lease Liabilities (Details)	Jun. 30, 2023 USD ($)
Leases
2023	$ 225,474
2024	348,881
2025	355,859
2026	362,976
Thereafter	401,139
Subtotal future lease payments	1,694,329
Less imputed interest	(333,408)
Total lease liabilities	$ 1,360,921
Operating lease, weighted average remaining lease term	4 years 5 months 8 days
Operating lease, weighted average discount rate, percent	9.98%

Leases (Details Narrative)

Leases (Details Narrative)		1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 09, 2019	Jan. 31, 2023 USD ($) ft²	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2011 ft²
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease operating, description							In 2011, the Company executed a lease (the “Lease”) with Brandywine Operating Partnership, L.P. (“Brandywine”), a Delaware limited partnership, for a 10,870 square foot premises located in Lawrenceville, New Jersey, and relocated its offices to Lawrenceville, New Jersey, from Columbia, Maryland. The Lease had an initial term of 66 months. In late 2015, Lenox Drive Office Park LLC assumed the Lease
Area of land | ft²							10,870
Operating lease, term							66 months
Operating lease, cost			$ 165,446	$ 146,936	$ 324,722	$ 293,872
Operating lease, payments			$ 173,753	$ 150,374	340,457	$ 299,947
1st Lease Amendment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease operating, description	increase the size of the premises by 2,285 square feet to 9,850 square feet and also extended the lease term by one year to September 1, 2023.
Second Lease Amendment [Member] | First Year [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for rent					25,035
Second Lease Amendment [Member] | Final Year [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for rent					$ 27,088
Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Area of land | ft²		11,420
Lease Agreement [Member] | Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for rent		$ 28,550
Lease Agreement [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for rent		$ 30,903

Technology Development and Li_2

Technology Development and Licensing Agreements (Details Narrative) - Hisun [Member] $ in Millions	Jan. 18, 2013 USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Proceeds from license fees received	$ 5
Deferred revenue	$ 5
Deferred revenue amortization period	10 years

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	Apr. 19, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Legal Fees	$ 583,500

Related Party Transaction (Deta

Related Party Transaction (Details Narrative) - Convertible Note Purchase Agreement [Member] - Transomic Technologies Inc [Member]	Nov. 16, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Convertable and warrants	$ 375,000
Interest rate, percentage	5%